AXSM - Axsome Therapeutics to Present at Three Upcoming Investor Conferences | Benzinga
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in three upcoming investor conferences in September. The presentation details are as follows:
- H.C. Wainwright 25th Annual Global Investment Conference, on September 12, 2023, at 12:30 p.m. Eastern Time. Dr. Tabuteau will participate in a fireside chat at the Lotte New York Palace Hotel, New York City.
- Morgan Stanley 21st Annual Global Healthcare Conference, on September 13, 2023, at 2:55 p.m. Eastern Time. Dr. Tabuteau will participate in a fireside chat at the Sheraton New York Times Square, New York City.
- TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit, on September 20, 2023, at 10:20 a.m. Eastern Time. Dr. Tabuteau will participate in a virtual fireside chat.
A live webcast and archive of the events can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic ...